A comparison of the anti-inflammatory activities of conjugated estrogens and 17-β estradiol

Inflammation Research

Volumn 52, Issue 11, 2003, Pages 452-460

  Thomas, T N ^a,b   Rhodin, J A ^a   Clark, L ^a   Garces, A ^a   Bryant, M ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b Woodlands Med and Research Center   (United States)

Author keywords

Alzheimer's disease; Cardiovascular disease; Estrogen; Inflammation; Menopause

Indexed keywords

AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; CELL MARKER; CONJUGATED ESTROGEN; ESTRADIOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CELL DISRUPTION; CONTROLLED STUDY; DOSE RESPONSE; ENDOTHELIUM CELL; FEMALE; IN VIVO STUDY; INFLAMMATION; LEUKOCYTE MIGRATION; MAST CELL; MAST CELL DEGRANULATION; MESENTERY; NONHUMAN; THROMBOCYTE ACTIVATION; TRANSMISSION ELECTRON MICROSCOPY; VASCULAR DISEASE; VIDEORECORDING;

AMYLOID BETA-PROTEIN; ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOOD PLATELETS; BLOOD VESSELS; CELL ADHESION; ESTRADIOL; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; INFLAMMATION; LEUKOCYTES; MAST CELLS; MESENTERY; MICROSCOPY, ELECTRON; MICROSCOPY, VIDEO; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0345377644     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00011-003-1198-0     Document Type: Article

References (43)

1. Thomas T. A role for estrogen in the primary prevention of Alzheimer's disease. Climacteric 2001; 4: 102-9.
2. Writing Group for Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy menopausal women: principal results from Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002; 288: 321-33.
3. Brod SA. Unregulated inflammation shortens human functional longevity. Inflamm Res 2000; 49: 561-70.
4. Ross R. Atherosclerosis - an inflammatory disease, New Engl J Med 1999; 340: 115-26.
5. Mendelsohn ME, Karas RH. The protective effect of estrogen on the cardiovascular system. New Engl J Med 1999; 340: 1810-1.
6. Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B et al. Effect of estrogen during menopause on risk and age onset of Alzheimer's disease. Lancet 1996; 348: 429-32.
7. Yaffe K, Lui L, Grady D, Cauley J, Kramer J, Cummings SR. Cognitive decline in women in relation to non-protein bound estradiol concentrations. Lancet 2000; 356: 708-12.
8. Koenig W. Inflammation and coronary heart disease: an overview. Cardiol Res 2000; 9: 31-5.
9. Thomas T, Rhodin JA, Sutton ET, Bryant WM, Price JM. Estrogen protects peripheral and cerebral blood vessels from toxicity of Alzheimer's peptide amyloid-β and inflammatory reaction. J Submicrosc Cytol Pathol 1999; 31: 571-9.
10. Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation and plaque stability. Cardiovasc Res 2000; 47: 648-57.
11. Hoffmeister A, Rothenbacher D, Bazner U, Frohlich M, Brenner H, Hombach V et al. Role of novel markers of inflammation in patients with stable coronary heart disease. Am J Cardiol 2001; 37: 262-6.
12. Thomas T. Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease. Neurobiol Aging 2000; 21: 343-8.
13. Kawas C, Resnik S, Morrison A, Brookmeyer R, Corrada M, Zonderman A et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease. The Baltimore longitudinal study. Neurology 1997; 54: 295-301.
14. Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC et al. Hormone replacement therapy and incidence of Alzheimer disease in older women. The Cache County study. Am J Med Assoc 2002; 288: 2123-9.
15. Henderson VW, Paganini-Hill A, Miller B, Elble RJ, Reyes PF, Shoupe D et al. Estrogen for Alzheimer's disease in women. Randomized, double blind, placebo-controlled trial. Neurology 2000; 54: 295-301.
16. McGeer PL, McGeer EG. Arthritis and anti-inflammatory agents as possible factors for Alzheimer's disease: a review of 27 epidemiologic studies. Neurology 1996; 47: 425-32.
17. McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer's disease and other neurodegenerative diseases. Brain Res Rev 1995; 21: 195-218.
18. Thomas T, Sutton ET, Bryant MW, Rhodin JAG. In vivo vascular damage, leukocyte activation and inflammatory response induced by β-amyloid. J Submicrosc Cytol Pathol 1997; 29: 293-304.
19. Rhodin J, Thomas T, Bryant MW, Sutton ET. Animal model of vascular inflammation. J Submicrosc Cytol Pathol 1999; 31: 305-14.
20. Thomas T, Bryant MW, Clark L, Garces A, Rhodin JA. Estrogen and raloxifen activities on amyloid-β induced inflammatory reaction. Microvasc Res 2001; 61: 28-39.
21. Rhodin J, Thomas T. A vascular connection to Alzheimer's disease. Microcirculation 2001; 8: 207-20.
22. Sutton ET, Thomas T, Bryant MW, Landon CS, Newton CA, Rhodin JAG. Amyloid-β-peptide-induced inflammatory reaction is mediated by the cytokines, tumor necrosis factor and interleukin-1. J Submicrosc Cytol Pathol 1999; 31: 313-23.
23. Chambers R, Zweifach BW. Topography and function of the mesenteric capillary circulation. Am J Anat 1944; 75: 173-206.
24. Zweifach BW. Direct observations of the mesenteric circulation in experimental animals. Anat Rec 1954; 120: 277-92.
25. Illig L. Die Kreislaufsmikroskopie am Mesenterium und Pankreas des lebenden Kaninchens. Zeitschr Gesellsch Exp Med. 1955; 126: 501-39.
26. Frasher WG, Wayland H. A repeating modular organization of the microcirculation of the cat mesentery. Microvasc Res 1972; 4: 62-76.
27. Frasher WG. Attached floating cat mesentery preparation for vital microscopy. Microvasc Res 1973; 5: 376-83.
28. Rhodin JAG. Perfusion and superfusion fixation effects on rat mesentery microvascular beds. Intravital and electron microscopy analyses. J Submicrosc Cytol Pathol 1986; 18: 453-70.
29. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M. β-amyloid- mediated vasoactivity and vascular endothelial dysfunction. Nature 1996; 380: 168-71.
30. Muller WA. Leukocyte-endothelial interaction in the inflammatory response. Lab Investig 2002; 82: 521-33.
31. Thomas T, Nadackal TG, Thomas K. Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-β aggregation. Neuro Report 2001; 12: 1-5.
32. Bhavnani BR. Pharmacokinetics and pharmacodynamics of conjugated equine estrogens: chemistry and metabolism. Proc Soc Exp Biol Med 1998; 217: 6-16.
33. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 1996; 382: 685-91.
34. Mackic J, Stins M, McComb J, Calero M, Ghiso J, Kim K, Yan S-D, Stern D, Schmidt A-M, Frangione B, Zlokovic B. Human blood-brain barrier receptors for Alzheimer's amyloid-β (1-40). J Clin Invest 1998; 102: 734-43.
35. Mendelsohn ME. Mechanisms of estrogen action in the cardiovascular system. J Steroid Biochem Molecul Biol 2000; 74: 337-43.
36. Sugiyama T. Involvement of interleukin-6 and prostaglandin E2 in periarticular osteoporosis of postmenopausal women with rheumatoid arthritis. J Bone Mineral Metabol 2001; 19: 89-96.
37. Maki PM, Resnick SM. Longitudinal effects of estrogen replacement therapy on PET cerebral blood flow and cognition. Neurobiol Aging 2000; 21: 373-83.
38. Hulley S, Grady D, Bush T, Furberg C, Herrington DM, Riggs B et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Assoc 1998; 280: 605-13.
39. Herrington DM, Reboussin DM, Brisnihan KB, Sharp PC, Shumaker SA, Snyder TD et al. Effect of estrogen replacement on progression of coronary artery atherosclerosis. New Engl J Med 2000; 343: 522-9.
40. Wang PN, Liao SQ, Liu RS, Liu CY, Chao HT, Lu SR et al. Effects of estrogen on cognition, mood and cerebral blood flow in Alzheimer's disease. Neurology 2000; 54: 2061-6.
41. Mulnard RA, Cotman CW, Kawas C, vanDyck CH, Sano M, Doody R et al. Estrogen replacement therapy for the treatment of mild to moderate Alzheimer's disease. A randomized controlled trial. Am J Med Assoc 2000; 283: 1007-15.
42. He S, Gaca MD, McEuen AR, Walls AR. Inhibitors of chymase as mast cell stabilizing agents: Contribution of chymase in the activation of human mast cells. J Pharmacol Exp Therapy 1999; 291: 517-23.
43. Kiener PA, Davis PM, Murray JL, Youseff S, Ranking BM, Kowala M. Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. Int. Immunopharmacol 2001; 1: 105-18.